Palatin Technologies, Inc. (PTN)
| Market Cap | 34.58M |
| Revenue (ttm) | 2.18M |
| Net Income (ttm) | -37.34M |
| Shares Out | 9.63M |
| EPS (ttm) | -0.16 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | Aug 31, 2022 |
| Volume | 15,216 |
| Open | 3.3 |
| Previous Close | 3.34 |
| Day's Range | 3.17 - 3.51 |
| 52-Week Range | 3.09 - 15 |
| Beta | 0.72 |
| Analysts | Buy |
| Price Target | 43.86 (+1,205.4%) |
| Earnings Date | Nov 14, 2022 |
About PTN
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a p... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for PTN stock is "Buy." The 12-month stock price forecast is 43.86, which is an increase of 1,205.36% from the latest price.
News
Palatin Technologies, Inc. (PTN) Reports Q1 Loss, Tops Revenue Estimates
Palatin Technologies, Inc. (PTN) delivered earnings and revenue surprises of 35.82% and 8.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the st...
Palatin Reports First Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Ongoing Positive Interim Analysis – DMC Recommended Study Size of 350 patients Topline Results Currently Expected Second Quarter Calendar...
Palatin to Report First Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on November 14, 2022
CRANBURY, N.J., Nov. 9, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter fiscal year 2023 operating results on Monday, November 14, 2022, before the o...
Palatin Announces $10 Million Registered Direct Offering
CRANBURY, N.J. , Oct. 31, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activ...
Palatin Presents PL8177 Data at American College of Gastroenterology Annual Meeting
Preclinical data shows efficacy in animal models of ulcerative colitis Human pharmacokinetic data show oral formulation releases PL8177 in colon CRANBURY, N.J. , Oct. 24, 2022 /PRNewswire/ -- Palatin Te...
First Patient Enrolled in Palatin's Phase 2 study of PL8177 in Ulcerative Colitis Trial
Oral PL8177 may provide an effective, safe, and tolerable treatment option for ulcerative colitis patients prior to being treated with immunosuppressive therapies, which have significant safety and tole...
Palatin Announces Preliminary First Quarter Fiscal 2023 Vyleesi® Product Sales Results
Net product revenue for prescriptions dispensed increased 20% Prescriptions dispensed increased 17%, over prior quarter Refills accounted for over 50% of prescriptions dispensed CRANBURY, N.J. , Oct. 13...
Palatin Announces Presentation at the Eyecelerator@AAO 2022 Conference
Overview of Development Pipeline of Melanocortins for Treatment of Ocular Conditions and Role in Resolving Inflammation PL9643 Phase 3 Study Results in Dry Eye Disease Currently Expected 2Q 2023 Palatin...
Palatin to Participate in Ladenburg Thalmann Healthcare Conference
CRANBURY, N.J. , Sept. 29, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the acti...
Palatin Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Corporate Update
Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Ongoing Positive Interim Analysis – DMC Recommended Study Sample Size of 350 Patients Topline Results Currently Expected Second Quarter C...
Palatin to Report Fourth Quarter and Fiscal Year End 2022 Results; Teleconference and Webcast to be held on September...
CRANBURY, N.J. , Sept. 19, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2022 operating results on Thursday, September 22, 202...
Palatin Announces Initiation of Patient Recruitment for Phase 2 Clinical Study Evaluating Oral PL8177 for Treatment o...
Study Designed to Evaluate the Safety, Tolerability, and Efficacy with PL8177 Oral Colon Delivery in Adult Subjects with Active Ulcerative Colitis Oral PL8177 May Provide a Safe and Tolerable Treatment ...
3 Penny Stocks That Could 10X by 2023
How do you find the best penny stocks? The answer may seem simple, but it's not.
Palatin Announces Intent to Effect Reverse Stock Split
Common Stock Will Begin Trading on a Split-Adjusted Basis on August 31, 2022 CRANBURY, N.J., Aug. 19, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company de...
Palatin Reports Positive Interim Analysis in Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease
Independent Data Monitoring Committee Recommends Continuing Study with Sample Size Target of up to 350 Patients – up to Additional 230 Patients to be Enrolled No Safety Concerns Identified Topline Resul...
Palatin Announces Preliminary Fourth Quarter Vyleesi® Net Product Revenue Increased 225% Over Prior Quarter
Gross product sales increased 75% and Prescriptions dispensed increased 45%, over prior quarter CRANBURY, N.J. , July 26, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharm...
Palatin Technologies, Inc. (PTN) Reports Q3 Loss, Misses Revenue Estimates
Palatin Technologies, Inc. (PTN) delivered earnings and revenue surprises of 0% and 62.76%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Palatin Reports Third Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update
Patient Enrollment on Track in Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease with Topline Results Currently Expected Second Half Calendar 2022 Vyleesi® - Gross product sales increased...
Palatin Announces $15 Million Private Placement of Convertible Redeemable Preferred Stock
CRANBURY, N.J. , May 12, 2022 /PRNewswire/ -- Palatin Technologies, Inc. ("Palatin" or the "Company") (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molec...
Palatin to Report Third Quarter, Fiscal Year 2022 Results; Teleconference and Webcast to be held on May 17, 2022
CRANBURY, N.J. , May 11, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter, fiscal year 2022 operating results on Tuesday, May 17, 2022, before the ope...
Palatin to Present at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Conference
Posters highlight Palatin's ocular research and PL9643 Phase 2 clinical data CRANBURY, N.J. , May 2, 2022 /PRNewswire/ -- Palatin Technologies, Inc. ("Palatin") (NYSE American: PTN), a biopharmaceutical...
Palatin to Present at Eyecelerator @ American Society of Cataract and Refractive Surgery (ASCRS) 2022
Presentation to review the role of melanocortins in the treatment of ocular disease and Phase 2 study results with Palatin's compound PL9643 for Dry Eye Disease PL9643 Dry Eye Disease Phase 3 study ongo...
Palatin Hosting Key Opinion Leader Webinar on Dry Eye Disease
CRANBURY, N.J. , March 3, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activ...
Palatin Reports Second Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update
CRANBURY, N.J., Feb. 15, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activi...
Palatin Technologies, Inc. (PTN) Reports Q2 Loss, Tops Revenue Estimates
Palatin Technologies, Inc. (PTN) delivered earnings and revenue surprises of -33.33% and 78.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the s...